Robert Johnson

Adrestia Therapeutics Ltd. engages in the development of therapeutics by restoring the biological balance in damaged, diseased or dying cells. The company was founded by Stephen Philip Jackson, Gabriel Balmus, Yaron Galanty and Rafael Carazo Salas and is headquartered in Cambridge, the United Kingdom.

Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA.